Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by longrun86on Apr 25, 2022 5:59pm
112 Views
Post# 34630442

RE:would love to know ...

RE:would love to know ...My view is that there is a ton of liquidity available for them to deploy though the combination of:

  1. Investments that are maturing (funds & debt) that should free up $190+ million over the next few years;
  2. Operating cash flow being generated; and
  3. Debt... the company is debt free and could use the shelf prospectus to borrow for the sake of borrowing; OR, borrow with the intention of repaying based on the return of investment capital.

Management has quite a few tools available to them should they find an opportunity to deploy capital. They need to demonstrate that they can (1) continue to execute in deploying capital AND (2) what they have deployed gets back to generating the return that was envisioned at the time of acquisition.

The next question is... what is out there for them that meets Knight's acquisition criteria!

LR 
<< Previous
Bullboard Posts
Next >>